Fig. 1 · Structure

Documents & Downloads

S3I-201 (NSC 74859)

Cat. No. A10817 CAS 501919-59-1

Stat3 Inhibitor

S3I-201 (NSC 74859) is a novel inhibitor of Stat3 that inhibits Stat3, Stat3 complex formation and Stat3-DNA binding activity in vitro (IC50 = 86 ± 33 μM) and Stat3-dependent transcriptional activities.

In Stock

Publications for S3I-201

4 publications citing this product

  1. Bae WJ, .et al. , J Exp Clin Cancer Res, 2019, 38:484 PMID: 31805999
  2. Ethan L. Morgan, .et al. , PLoS Pathog, 2018, Apr; 14(4): e1006975 PMID: 29630659
  3. Nishimura K, .et al. , Biochem Biophys Res Commun, 2018, Jan 1;495(1):1317-1321 PMID: 29191652
  4. Soleimani AH, .et al. , Drug Deliv Transl Res, 2017, Aug;7(4):571-581 PMID: 28290050

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

S3I-201 (NSC 74859) inhibited STAT3 DNA binding in a nuclear-extract EMSA, with a reported IC50 of 86 ± 33 μM. STAT1-containing and STAT5 complexes were less sensitive in the tested assays. This endpoint is an assay-specific inhibition measurement. [1]

Interpret S3I-201 responses with chemical-reactivity controls. A later study found rapid reaction with glutathione and detected covalent modification at multiple STAT3 cysteines. These findings limit interpretation of S3I-201 as a selective, noncovalent STAT3 SH2 probe. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
STAT3 (Cell-free assay) 86 μM

Cellular Effect

Cell Line Activity Value Description Reference
NIH3T3 IC50 > 300 μM Inhibition of STAT1 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1-DNA interaction after 30 mins by EMSA [PMID: 22650325]
NIH3T3 IC50 160 μM Inhibition of STAT1/STAT3 in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1/STAT3-DNA interaction after 30 mins by EMSA [PMID: 22650325]
NIH3T3 IC50 86 μM Inhibition of STAT3 dimerization in v-Src transformed mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT3-DNA interaction in nucleus after 30 mins by EMSA [PMID: 22650325]
NIH3T3 IC50 86 μM Inhibition of STAT3 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT3-DNA interaction after 30 mins by EMSA [PMID: 22650325]

S3I-201 (NSC 74859) Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of S3I-201 (NSC 74859) from 3 published references.

S3I-201 (NSC 74859) In Vitro Studies

In PTPRD-silenced MKN74 and SNU216 gastric-cancer cells, S3I-201 (100 μM, 48 h) reduced elevated CXCL8 mRNA and secreted CXCL8. These model-specific responses do not establish that the compound acts exclusively through STAT3. [2,3]

STAT-family DNA-binding inhibition in nuclear extracts

Biochemical assay · Nuclear extracts from NIH 3T3/v-Src cells and EGF-stimulated NIH 3T3/hEGFR fibroblasts. [1]

S3I-201 inhibited STAT3 DNA binding, with weaker inhibition of STAT1-containing and STAT5 complexes in the tested extract assays. These are assay-specific comparisons, not proteome-wide selectivity evidence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
STAT3:STAT3 DNA bindingIC50 86 ± 33 μM[1]
STAT1:STAT3 DNA bindingIC50 160 ± 43 μM[1]
STAT1:STAT1 DNA bindingIC50 >300 μM[1]
STAT5:STAT5 DNA bindingIC50 166 ± 17 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
30 min preincubation at room temperature before labeled probe
Method
Cell-free nuclear-extract EMSA with hSIE or MGFe probes; band densitometry relative to vehicle control
Vehicle
0.05% DMSO
Reported limits
Exact concentration series beyond displayed lanes and replicate count/meaning of ± for the reported IC50 estimates are not specified in the adopted passage.
Methods and source locations

Compound reported in the paper: S3I-201 (NSC 74859); Compound label in the paper: S3I-201

Research on the named compound; no validation of the current catalog lot, clinical efficacy or a salt-equivalent dose.

Results: Identification of a Chemical Probe as Inhibitor of Stat3 DNA-Binding Activity; Fig. 2A and caption; nuclear extract/EMSA methods; displayed S3I-201 structure

STAT3:STAT3 DNA binding: EMSA; reported in Results, not estimated from image. ± retained without assigning SD or SEM. — Results: Identification of a Chemical Probe as Inhibitor of Stat3 DNA-Binding Activity; Fig. 2A and caption; nuclear extract/EMSA methods; displayed S3I-201 structure

STAT1:STAT3 DNA binding: EMSA; reported in Results, not estimated from image. ± retained without assigning SD or SEM. — Results: Identification of a Chemical Probe as Inhibitor of Stat3 DNA-Binding Activity; Fig. 2A and caption; nuclear extract/EMSA methods; displayed S3I-201 structure

STAT1:STAT1 DNA binding: EMSA; reported in Results, not estimated from image. ± retained without assigning SD or SEM. — Results: Identification of a Chemical Probe as Inhibitor of Stat3 DNA-Binding Activity; Fig. 2A and caption; nuclear extract/EMSA methods; displayed S3I-201 structure

STAT5:STAT5 DNA binding: EMSA; reported in Results, not estimated from image. ± retained without assigning SD or SEM. — Results: Identification of a Chemical Probe as Inhibitor of Stat3 DNA-Binding Activity; Fig. 2A and caption; nuclear extract/EMSA methods; displayed S3I-201 structure

Glutathione reactivity and a less-reactive structural control

Biochemical assay · Cell-free HPLC chemical-stability assay with glutathione; sulfonamide analogue DB-5-112 as structural control. [2]

S3I-201 reacted rapidly with glutathione under the tested buffered conditions. DB-5-112 showed no reactivity under the same conditions. This is a chemical-reactivity result, not an in vivo half-life or cellular IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Parent-compound decay in GSH-containing bufferreaction t1/2 0.25 h[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM S3I-201 with 10 mM GSH and 10 mM TCEP-HCl in 50 mM HEPES, pH 7.4
Exposure duration
Time course up to 10 h
Method
HPLC peak-area decay; one-phase exponential fitting; method specifies three replicates
Vehicle
DMSO stock; 10 μL of 10 mM stock added to 990 μL reaction buffer
Reported limits
Replicate independence is not defined; fitted supplementary-table uncertainties were not retrieved.
Methods and source locations

Compound reported in the paper: S3I-201 (NSC 74859); Compound label in the paper: S3I-201

Research on the named compound; no validation of the current catalog lot, clinical efficacy or a salt-equivalent dose.

Results: S3I-201’s reactivity toward glutathione; Fig. 1A-C and caption; In vitro chemical stability assays

Parent-compound decay in GSH-containing buffer: Reported Results value; HPLC kinetic fit, three replicates in methods. Not estimated from plotted points. — Results: S3I-201’s reactivity toward glutathione; Fig. 1A-C and caption; In vitro chemical stability assays

Direct detection of covalent STAT3 modification

Biochemical assay · Recombinant full-length STAT3, incubated in the presence or absence of S3I-201, followed by tryptic LC-MS/MS. [2]

The main-figure spectra support covalent modification at Cys259, Cys367, Cys542 and Cys687. The authors also report Cys108, but its supplementary spectrum was not retrieved and that additional site is not adopted here. Multiple adduct sites challenge a simple selective SH2-binding interpretation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
STAT3 covalent-adduct sites supported in main Fig. 3identified residues Cys259, Cys367, Cys542, Cys687[2]

Literature-Reported Treatment Conditions

Treatment concentration
500 μM S3I-201; Results describe an 80-fold molar excess over STAT3
Exposure duration
1 h at 37°C
Method
LC-MS/MS of digested full-length STAT3; matched incubation without S3I-201
Vehicle
Not specified in adopted mass-spectrometry method
Reported limits
Replicate count and compound-delivery solvent not specified in adopted method. Cys108 SI spectrum not retrieved.
Methods and source locations

Compound reported in the paper: S3I-201 (NSC 74859); Compound label in the paper: S3I-201

Research on the named compound; no validation of the current catalog lot, clinical efficacy or a salt-equivalent dose.

Results: Incubation of STAT3 with S3I-201, tryptic digestion and LC-MS/MS analysis; Fig. 3 and caption; Mass spectrometry methods

STAT3 covalent-adduct sites supported in main Fig. 3: LC-MS/MS fragment-ion assignments; image and Results checked. No adduct occupancy or site selectivity estimate adopted. — Results: Incubation of STAT3 with S3I-201, tryptic digestion and LC-MS/MS analysis; Fig. 3 and caption; Mass spectrometry methods

CXCL8 response in PTPRD-silenced gastric-cancer cells

Cell-based study · MKN74 and SNU216 gastric-cancer cells with stable PTPRD knockdown (shPTPRD), compared with shNS and untreated shPTPRD conditions. [3]

S3I-201 reduced CXCL8 mRNA and secreted CXCL8 elevated after PTPRD knockdown in both models. The paired expression/secretion endpoints are one coherent cellular experiment. These pharmacological responses do not establish STAT3-exclusive mediation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CXCL8 mRNA after S3I-201, relative to untreated shPTPRD conditiondirection Reduced in MKN74 and SNU216 cells[3]
Secreted CXCL8 after S3I-201, relative to untreated shPTPRD conditiondirection Reduced in MKN74 and SNU216 cells[3]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM
Exposure duration
48 h
Method
Separate S3I-201 treatment; CXCL8 qRT-PCR normalized to β-actin and secreted CXCL8 ELISA
Vehicle
Not specified in adopted locations
Reported limits
Exact vehicle and within-experiment technical replicate count not specified. No exact bar-height values extracted.
Methods and source locations

Compound reported in the paper: S3I-201 (NSC 74859); Compound label in the paper: S3I-201

Research on the named compound; no validation of the current catalog lot, clinical efficacy or a salt-equivalent dose.

Reagents and antibodies; Results: Loss of PTPRD activated ERK/STAT3; Fig. 4C-D and caption; RT/qRT-PCR and ELISA methods

CXCL8 mRNA after S3I-201, relative to untreated shPTPRD condition: Fig. 4C-D lower panels; qRT-PCR; caption: representative of three independent experiments, unpaired Student’s t-test. — Reagents and antibodies; Results: Loss of PTPRD activated ERK/STAT3; Fig. 4C-D and caption; RT/qRT-PCR and ELISA methods

Secreted CXCL8 after S3I-201, relative to untreated shPTPRD condition: Fig. 4C-D upper panels; ELISA; no numerical pg/mL estimate from bars. — Reagents and antibodies; Results: Loss of PTPRD activated ERK/STAT3; Fig. 4C-D and caption; RT/qRT-PCR and ELISA methods

S3I-201 (NSC 74859) In Vivo Studies

S3I-201 (5 mg/kg intravenously every 2 or 3 days for 2 weeks) strongly inhibited MDA-MB-231 xenograft growth in female athymic nude mice versus vehicle. The study reports eight tumor-bearing mice per group; the small tumor-lysate subset used for STAT3 DNA-binding analysis does not establish target-exclusive causality. [1]

Breast-tumor growth inhibition in nude mice

Animal study · Female athymic nude mice bearing human MDA-MB-231 breast-tumor xenografts. [1]

Tumor growth was strongly inhibited relative to vehicle. Endpoint tumor lysates from one control and two treated animals showed reduced STAT3 DNA-binding activity; this small tissue subset does not establish target-exclusive causality. No exact tumor-volume percentage is inferred.

Conditions shared by the study groups

Route
intravenous
Frequency
every 2 or every 3 days
Treatment course
2 weeks
Vehicle
DMSO-treated control; injected vehicle composition/concentration not specified in adopted text
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
S3I-201 versus vehicle
5 mg/kg
Vehicle-treated tumor-bearing miceStrong tumor-growth inhibition; Fig. 6A reports mean ± SD for eight tumor-bearing mice each. Fig. 6B shows reduced STAT3 DNA binding in residual tumors from two treated mice compared with one control.[1]
S3I-201 versus vehicle
Model: Female athymic nude mice bearing human MDA-MB-231 breast-tumor xenografts.
Reported limits: Randomization/blinding and full injected formulation not specified in adopted locations. No pharmacokinetic or formal systemic-toxicity conclusion adopted.
Methods and source locations

Compound reported in the paper: S3I-201 (NSC 74859); Compound label in the paper: S3I-201

Research on the named compound; no validation of the current catalog lot, clinical efficacy or a salt-equivalent dose.

Results: S3I-201 Induces Regression of Human Breast Tumor Xenografts; Fig. 6A-B and caption; Mice and in Vivo Tumor Studies

S3I-201 versus vehicle · Results: S3I-201 Induces Regression of Human Breast Tumor Xenografts; Fig. 6A-B and caption; Mice and in Vivo Tumor Studies

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 501919-59-1
Applications Stat3 Inhibitor
Formula C16H15NO7S
Molecular Weight 365.4
Synonyms NSC74859
SMILES
CC1=CC=C(C=C1)S(=O)(=O)OCC(=O)NC2=CC(=C(C=C2)C(=O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 66 mg/mL (180.64 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
2 mg/mL
Vehicle
5% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

S3I-201 (NSC 74859) Research References

  1. [1] Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity Proceedings of the National Academy of Sciences of the United States of America (2007). PMID: 17463090 DOI: 10.1073/pnas.0609757104 Source material
  2. [2] Ball DP, Lewis AM, Williams D, et al. Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent Oncotarget (2016). PMID: 26942696 DOI: 10.18632/oncotarget.7838 Source material
  3. [3] Bae WJ, Ahn JM, Byeon HE, et al. PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin Journal of experimental & clinical cancer research : CR (2019). PMID: 31805999 DOI: 10.1186/s13046-019-1469-4 Source material

Publications

4 publications citing this product

  1. Bae WJ, .et al. , J Exp Clin Cancer Res, 2019, 38:484 PMID: 31805999
  2. Ethan L. Morgan, .et al. , PLoS Pathog, 2018, Apr; 14(4): e1006975 PMID: 29630659
  3. Nishimura K, .et al. , Biochem Biophys Res Commun, 2018, Jan 1;495(1):1317-1321 PMID: 29191652
  4. Soleimani AH, .et al. , Drug Deliv Transl Res, 2017, Aug;7(4):571-581 PMID: 28290050

Added to your cart

View Cart Checkout
Loading...